CD68 and rheumatoid arthritis: In the treatment of rheumatoid arthritis, changes in the number of CD68+ macrophages are associated with clinical outcomes assessed by DAS28 and are considered a reliable biomarker for assessing the efficacy of rheumatoid arthritis treatments (Haringman et al., 2005).